Low Dose Naltrexone Use in Patients With POTS

Launched by UNIVERSITY OF CALGARY · May 2, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a medication called low dose naltrexone (LDN) to see if it can help people with Postural Orthostatic Tachycardia Syndrome (POTS) feel less tired. Many people with POTS struggle with extreme fatigue, which makes daily activities difficult. Previous research has shown that LDN may help reduce fatigue in other conditions and also lower inflammation in the body. This is the first study specifically looking at LDN for POTS, and researchers hope it will provide new options for improving the quality of life for patients.

To participate in this study, you need to have a confirmed diagnosis of POTS and be able to attend research locations in Calgary, Vancouver, or Hamilton, Canada. You must also be between the ages of 18 and 62, not pregnant or breastfeeding, and able to continue your regular medications during the study. Participants will receive the medication and be monitored closely to see how it affects their fatigue and overall symptoms. It's important to note that this study is not yet recruiting participants, but if you're interested, it could be a great opportunity to contribute to understanding new treatments for POTS.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Physician diagnosis of POTS as defined by the American Autonomic Society consensus statement
• • Ability to attend research lab in Calgary, Vancouver or Hamilton, Canada
• • Not pregnant and not planning to become pregnant for the duration of the study
• • Maintain current other medications at regular doses for the duration of the study
• Exclusion Criteria:
• • Overt cause for postural tachycardia (e.g. acute dehydration, hyperthyroidism)
• • Positive pregnancy test
• • Breastfeeding
• • Other factors which in the investigator's opinion would prevent participant from completing the protocol, including poor compliance during previous studies
• • Current use of Low Dose Naltrexone
• • Use of opioid containing medications or positive urine opioid test
• • History of alcohol, opioid or other substance use disorder